Dedicated to discovery & development of important medicines to transform the lives of patients & their families
Clinical Trials
Global Clinical Development
Ascentage Pharma (6855.HK), is a global, clinical-stage biotechnology company engaged in developing novel first-in-class and best-in-class therapies for cancers and chronic hepatitis B. Ascentage expertise in programmed cell death will bring innovative therapies to patients across the world.
Learn more on ClinicalTrials.gov.
25 Clinical Trials Ongoing
-
Lymphoma, Solid Tumors
Alrizomadlin (APG-115)
APG-115 in patients with advanced solid tumors or lymphoma (APG-115)
MOLECULE: Alrizomadlin (APG-115)
CONDITION: Advanced solid tumors or lymphoma -
Small Cell Lung Cancer, Solid Tumors
Pelcitoclax (APG-1252)
A study of APG-1252 in patients with SCLC or other solid tumors
MOLECULE: Pelcitoclax (APG-1252)
CONDITION: SCLC or other solid tumors -
Hematologic Malignancies, Solid Tumors
APG-1387
APG-1387 in patients with advanced solid tumors or hematologic malignancies
MOLECULE: APG-1387
CONDITION: Advanced solid tumors or hematologic malignancies -
AML
APG-2575
A phase Ib study of the safety, PK of APG-2575 single agent and in combination with homoharringtonine or azacitidine in patients with relapsed/refractory AML
MOLECULE: APG-2575
CONDITION: Relapsed/Refractory AML -
Leukemia
Alrizomadlin (APG-115)
A phase IIA study evaluating the PK, safety and efficacy of APG-115 as a single agent or in combination with APG-2575 in subjects with T-cell prolymphocytic leukemia (T-PLL)
MOLECULE: Alrizomadlin (APG-115)
CONDITION: T-Cell Prolymphocytic Leukemia -
CLL/SLL
APG-2575
A phase Ib/II study of the safety, pharmacokinetic, pharmacodynamic and efficacy of APG-2575 single agent and in combination with other therapeutic agents in patients with relapsed/refractory CLL/SLL
MOLECULE: APG-2575
CONDITION: Relapsed/Refractory CLL/SLL -
CLL/SLL
Alrizomadlin (APG-115)
A phase Ib/II study of APG-115 alone or in combination with azacitidine in patients with relapsed/refractory AML
MOLECULE: Alrizomadlin (APG-115)
CONDITION: Relapsed/Refractory AML -
Solid Tumors
APG-1387
A phase Ib/II clinical study to evaluate the efficacy and safety of APG-1387 in combination with toripalimab in patients with advanced solid tumors
MOLECULE: APG-1387
CONDITION: Advanced Solid Tumors -
AML, MDS
Alrizomadlin (APG-115)
A phase Ib study of APG-115 single agent or in combination with azacytidine or cytarabine in patients with AML and MDS
MOLECULE: Alrizomadlin (APG-115)
CONDITION: AML and MDS -
Waldenström Macroglobulinemia (MAPLE-1)
APG-2575
APG-2575 single agent or in combination with ibrutinib or rituximab in patients with Waldenström macroglobulinemia (MAPLE-1)
MOLECULE: APG-2575
CONDITION: Waldenström Macroglobulinemia (MAPLE-1) -
Leukemia
HQP1351
Study of HQP1351 in subjects with refractory chronic myeloid leukemia (HQP1351CU101)
MOLECULE: HQP1351
CONDITION: Refractory Chronic Myeloid Leukemia -
CLL/SLL
APG-2575
Study of APG-2575 as a single agent or in combination with other therapeutic agents for CLL/SLL
MOLECULE: APG-2575
CONDITION: CLL/SLL -
Small Cell Lung Cancer
Pelcitoclax (APG-1252)
A multicenter, phase I/II study of combination APG-1252 plus paclitaxel in patients with relapsed/refractory small cell lung cancer
MOLECULE: Pelcitoclax (APG-1252)
CONDITION: Relapsed/Refractory Small Cell Lung Cancer -
Leukemia
HQP1351
The absorption, metabolism and excretion of [14C]HQ{1351 in humans
MOLECULE: HQP1351
CONDITION: Leukemia -
Leukemia
HQP1351
A phase 2, randomized, open-label, pivotal study to evaluate the efficacy and safety of HQP1351 in CML CP patients who are resistant and/or intolerant to first- and second-generation tyrosine kinase inhibitors
MOLECULE: HQP1351
CONDITION: Chronic Myeloid Leukemia -
NSCLC
Pelcitoclax (APG-1252)
A study of APG-1252 plus osimertinib (AZD9291) in EGFR TKI resistant NSCLC patients
MOLECULE: Pelcitoclax (APG-1252)
CONDITION: Non Small Cell Lung Cancer -
Solid Tumors
APG-2449
APG-2449 in patients with advanced solid tumors
MOLECULE: APG-2449
CONDITION: Advanced Solid Tumors -
Hematologic Malignancies
APG-2575
A study to evaluate the safety, PK and PD of APG-2575 in patients with hematologic malignancies
MOLECULE: APG-2575
CONDITION: Hematologic Malignancies -
Leukemia
HQP1351
A phase II multicenter, open-label study of HQP1351 in Chinese patients of chronic myeloid leukemia with T315I mutation in accelerated phase
MOLECULE: HQP1351
CONDITION: Chronic Myeloid Leukemia -
p53 Wild-Type Salivary Gland Carcinoma
Alrizomadlin (APG-115)
A multicenter phase I/II trial of a novel MDM2 inhibitor (APG-115) with or without platinum chemotherapy in p53 wild-type salivary gland carcinoma
MOLECULE: Alrizomadlin (APG-115)
CONDITION: p53 Wild-Type Salivary Gland Carcinoma -
Solid Tumors
Alrizomadlin (APG-115)
A study of APG-115 in combination with pembrolizumab in patients with metastatic melanoma or advanced solid tumors
MOLECULE: Alrizomadlin (APG-115)
CONDITION: Metastatic Melanoma and Advanced Solid Ttumors -
Solid Tumors
HQP1351
A study of HQP1351 in patients with GIST or other solid tumors
MOLECULE: HQP1351
CONDITION: GIST or Other Solid Tumors -
Chronic Hepatitis B
APG-1387
A phase I study of the safety, pharmacokinetic and pharmacodynamic properties of APG-1387 in patients with chronic hepatitis B
MOLECULE: APG-1387
CONDITION: Chronic Hepatitis B -
Hematologic Malignancies
APG-2575
APG-2575 study of safety, tolerability [and] PK/PD in patients with hematologic malignancies
MOLECULE: APG-2575
CONDITION: Hematologic Malignancies -
Small Cell Lung Cancer, Solid Tumors
Pelcitoclax (APG-1252)
A phase I study of the safety, pharmacokinetic and pharmacodynamic properties of intravenously administered APG-1252 in patients with small cell lung cancer (SCLC) or advanced solid tumors
MOLECULE: Pelcitoclax (APG-1252)
CONDITION: Small Cell Lung Cancer (SCLC), Advanced Solid Tumors